Reviewing Immunomedics (IMMU) and Arsanis (ASNS)

Immunomedics (NASDAQ: IMMU) and Arsanis (NASDAQ:ASNS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Valuation & Earnings

This table compares Immunomedics and Arsanis’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunomedics $3.09 million 858.41 -$153.20 million ($1.86) -8.60
Arsanis N/A N/A -$22.97 million N/A N/A

Arsanis has lower revenue, but higher earnings than Immunomedics.

Profitability

This table compares Immunomedics and Arsanis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immunomedics -7,187.83% N/A -76.04%
Arsanis N/A N/A N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Immunomedics and Arsanis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunomedics 0 0 3 0 3.00
Arsanis 0 0 4 0 3.00

Immunomedics currently has a consensus price target of $21.00, suggesting a potential upside of 31.25%. Arsanis has a consensus price target of $25.33, suggesting a potential upside of 105.28%. Given Arsanis’ higher probable upside, analysts clearly believe Arsanis is more favorable than Immunomedics.

Insider & Institutional Ownership

76.0% of Immunomedics shares are owned by institutional investors. 6.6% of Immunomedics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Arsanis beats Immunomedics on 5 of the 8 factors compared between the two stocks.

About Immunomedics

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

About Arsanis

Arsanis, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company’s mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500. Its lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically ventilated patients heavily colonized with Staphylococcus aureus in their respiratory tracts. Its ASN200 addresses the unmet medical need caused by drug-resistant extra-intestinal escherichia coli infections. Its ASN300 addresses the unmet medical need due to carbapenem-resistant klebsiella pneumoniae infections. Its ASN400 addresses the unmet medical need due to streptococcus pneumoniae, a leading cause of mortality among the elderly. The ASN500 program consisting of potent mAbs targeting respiratory syncytial virus (RSV).

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply